156 results
POS AM
CANF
Can-Fite Biopharma Ltd
5 Apr 24
Prospectus update (post-effective amendment)
4:15pm
be approximately $20.4 million. We intend to use the net proceeds of such warrant exercise, if any, for research and development, general
6-K
EX-99.1
CANF
Can-Fite Biopharma Ltd
28 Mar 24
Can-Fite Reports 2023 Financial Results and Clinical Update
7:05am
.
Research and development expenses for the year ended December 31, 2023 were $5.98 million, a decrease of $1.78 million, or 22.9%, compared to $7.76 million … for the year ended December 31, 2022. Research and development expenses for the year ended December 31, 2023 comprised primarily of expenses
F-3/A
CANF
Can-Fite Biopharma Ltd
28 Dec 23
Shelf registration (foreign) (amended)
4:16pm
of such warrant exercise, if any, for research and development, general and administrative expenses, and for working capital purposes.
Pending
F-3
CANF
Can-Fite Biopharma Ltd
12 Dec 23
Shelf registration (foreign)
4:15pm
intend to use the net proceeds of such warrant exercise, if any, for research and development, general and administrative expenses, and for working
6-K
EX-99.1
4ci1xn37vrmcwa wci4q
30 Nov 23
Can-Fite Reports Third Quarter 2023 Financial Results and Clinical Update
7:05am
424B3
untgssj80lpzz
22 Nov 23
Prospectus supplement
4:20pm
6-K
kmhz8dbutyzsny s91w9
22 Nov 23
Report of Foreign Private Issuer
4:15pm
6-K
EX-99.1
fgxipnqftbrki
21 Nov 23
Can-Fite Announces Exercise of Warrants for Approximately $3.0 Million in Gross Proceeds
4:30pm
6-K
EX-99.1
reiiy9
26 Oct 23
Can-Fite to Harness Artificial Intelligence to Develop Novel Anti-Cancer Drugs
7:11am
POS AM
7mj7cn4 lfl
1 Sep 23
Prospectus update (post-effective amendment)
4:16pm
F-3
ohy749l77r
1 Sep 23
Shelf registration (foreign)
4:15pm
6-K
EX-99.1
ws90s1pp13xwidr5q
31 Aug 23
Report of Foreign Private Issuer
7:12am
6-K
EX-99.3
zwd5m12pulr17k7replv
31 Aug 23
Report of Foreign Private Issuer
7:12am
6-K
EX-99.2
0u7i nv2t
31 Aug 23
Report of Foreign Private Issuer
7:12am
6-K
EX-99.1
uuybyrx
1 Jun 23
Can-Fite Reports First Quarter 2023 Financial Results & Provides Clinical Update
7:07am
6-K
EX-99.1
dhawjomtr awi
30 May 23
Report of Foreign Private Issuer
7:14am
POS AM
4zbr hw0s10jdz
21 Apr 23
Prospectus update (post-effective amendment)
4:16pm
POS AM
exrrhbfkf
31 Mar 23
Prospectus update (post-effective amendment)
4:30pm
6-K
EX-99.1
igpw74l m1700kpic09
30 Mar 23
Can-Fite Reports 2022 Financial Results & Provides Clinical Update
7:56am